Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold

Inclusion Criteria: 1. Male and female aged between 30 and 70 years, inclusive 2. Subjects who want improvement of bilateral nasolabial folds that are rated as 3 or 4 points on Wrinkle Severity Rating Scale 3. Subjects with visually symmetrical bilateral nasolabial folds 4. Subjects who consent to abstain from wrinkle improvement treatment in the lower face (below the lower orbital rim) during this trial 5. Subjects who are capable of understanding and following instructions, and participating in the entire course of the trial 6. Subjects who voluntarily decide to participate in this trial and provide written consent in the Informed Consent Form Exclusion Criteria: 1. Subjects who administered an anticoagulant (except for low-dose aspirin (100mg, up to 300mg/day) or equivalent) within 2 weeks prior to screening 2. Subjects who had face-lift, soft tissue augmentation, medium or deeper peeling, or dermal photo-rejuvenation on the lower face (lower orbital rim) for wrinkle improvement within 6 months prior to screening 3. Subjects who received treatment with calcium hydroxyapatite(CaHA) at the investigational medical device injection site within 1 year from screening 4. Subjects who have implanted a permanent expander prosthesis at the investigational medical device injection site, such as soft-form or silicon 5. Subjects with a scar or skin lesion at the investigational medical device injection site that may interfere with judgment of the treatment effect 6. Subjects with a history of anaphylaxis or severe complicated allergy or allergy to lidocaine or hyaluronic acid products 7. Subjects with a history of a hypertrophic scar or keloid 8. Subjects with a skin disease or wound infection at the investigational medical device injection site 9. Subjects who participated in another clinical trial within 30 days prior to screening 10. Pregnant or breastfeeding women or women of childbearing potential who are not using medically acceptable contraception or not consenting to practice birth control from screening to the end of trial 11. Subjects who are otherwise determined by the investigator as ineligible for this study